TCG Lifesciences Pvt. Ltd. (TCGLS) is a global contract research organisation (CRO) and contract development and manufacturing organisation (CDMO) delivering integrated research and development services to pharmaceutical, biotechnology, and related industries. Founded in 2001 and headquartered in Kolkata, India, the company has established a presence across the United States, Europe, and Japan.

The company supports the full drug discovery and development lifecycle through a multidisciplinary platform that combines chemistry, biology, and manufacturing capabilities. Its scientific workforce includes more than 1,300 professionals, with a significant proportion holding doctoral qualifications, enabling the delivery of specialised and integrated project solutions.

TCG Lifesciences focuses on multiple therapeutic areas, including inflammation and pain, infectious diseases, central nervous system disorders, and oncology. Its infrastructure includes advanced chemistry and biology laboratories, an AAALAC-certified animal facility, BSL-2 laboratories, electrophysiology capabilities, and cGMP kilo labs, alongside US FDA-accredited manufacturing operations.

Through its subsidiaries and manufacturing units, the company also provides contract manufacturing services, including API production, intermediates, and regulatory starting materials, supporting both development and commercial supply requirements.

Key Products and Services

• Drug discovery and early development services
• Chemistry synthesis and medicinal chemistry
• In vitro and in vivo pharmacology
• DMPK (drug metabolism and pharmacokinetics)
• Analytical development and validation
• Data science and integrated project support
• Custom API and intermediate manufacturing
• Process development, optimisation, and scale-up
• cGMP manufacturing and regulatory starting materials (RSMs)
• Technology transfer and commercial manufacturing support

TCG Lifesciences positions itself as an integrated partner across the drug lifecycle, combining research, development, and contract manufacturing capabilities to support global pharmaceutical and biotechnology companies. Its model is centred on delivering coordinated scientific expertise, scalable processes, and end-to-end solutions from discovery through to commercialisation.